AUS
NZ
UK
CA
USA
IND
Highlights
New preclinical findings highlight a treatment prospect targeting VISTA in triple-negative breast cancer
Preclinical results suggest HMBD-002 may suppress tumour growth by modulating immune and growth pathways
Therapeutic potential expands beyond TNBC with promising signs in head and neck cancer models
asx 200 listed Percheron Therapeutics Ltd (ASX:PER) has released new preclinical data for its immunotherapy candidate, HMBD-002, offering insight into its potential role in treating triple-negative breast cancer (TNBC).
The therapy has shown activity in animal models, demonstrating the ability to suppress tumour growth in TNBC cases associated with VISTA checkpoint expression. This finding underscores the therapeutic promise of HMBD-002 in a disease known for limited treatment options and poor response to conventional approaches.
VISTA as a Target in Triple-Negative Breast Cancer
TNBC remains one of the most challenging forms of breast cancer due to its aggressive nature and lack of targeted treatment pathways. The identification of VISTA as a contributor to immune evasion in a subset of TNBC cases presents a focused opportunity for intervention.
The drug’s mechanism is designed to block this immune checkpoint, enabling the body’s immune system to combat tumour cells more effectively. These findings stem from a collaboration with researchers who evaluated HMBD-002's potential in modulating immune response where traditional treatments have shown limited effectiveness.
Dual-Action Approach Offers Potential Therapeutic Edge
In contrast to conventional therapies that focus exclusively on immune activation, HMBD-002 appears to influence both immune suppression and cellular growth pathways. This dual-functionality may provide an advantage in overcoming resistance observed with single-target treatments.
The ability to interfere with EGFR-linked growth signals in addition to VISTA inhibition may position HMBD-002 as a differentiated option for oncological treatment, particularly in cases that have not responded to established checkpoint inhibitors.
Wider Applications Beyond Breast Cancer
Beyond TNBC, HMBD-002 has also shown early promise when paired with radiotherapy in squamous cell carcinoma of the head and neck. Experimental data suggest that this approach may enhance radiotherapy’s effectiveness by sensitising tumours and amplifying immune activity.
These findings may support HMBD-002’s broader applicability across multiple cancer types, particularly where immunosuppressive environments limit standard therapy outcomes.
Strategic Outlook for Clinical Development
Percheron’s research focus now turns to further clinical evaluation of HMBD-002, with plans to progress into phase II studies targeting TNBC patients expressing VISTA. Additional trial data from the ongoing phase I studies are anticipated to offer clarity on safety and tolerability across broader indications.
Engagement with clinical stakeholders and research partners will be pivotal as the company advances HMBD-002’s development strategy. The data presented reinforce Percheron’s commitment to addressing critical gaps in oncology care through targeted innovation.
Frequently Asked Questions
- What is HMBD-002?
It is an investigational therapy targeting immune checkpoints and growth signals. - Which cancer type is the focus of the latest study?
The preclinical data centres on triple-negative breast cancer (TNBC). - Is Percheron Therapeutics part of any ASX category?
Yes, it is part of the asx 200 list.
